CAMBRIDGE VISION TECHNOLOGY

Cambridge Vision Technology (CVT) provides AI-based technology for the early detection of Alzheimer’s Disease Dementia using ocular biomarkers. Early detection technologies for Alzheimer’s disease are urgently needed to maximise the effectiveness of recently approved disease-modifying therapies. These drugs slow down the progression of Alzheimer’s disease, making early administration crucial. Existing biomarkers are expensive, invasive, and lack scalability for population-level early detection. CVT’s innovative approach enables these therapies and maximises their clinical outcomes, offering significant economic and societal benefits.